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CME ARTICLE
IBD LIVE

IBD LIVE Case Series—Case 6: Persistent Skin Lesions in a Patient
with Crohn’s Disease: You Hear Hoof Beats and Discover a Zebra

LEARNING OBJECTIVES

PRESENTATION

After completing this IBD LIVE-CME activity, physicians
should be better able to:

Dr. D. Rajan: University of Maryland, Baltimore,
Advanced Inﬂammatory Bowel Disease Fellow, 2015 to 2016,
Presentation date: June 25, 2015.
The patient is a 27-year-old white man with a history of
inﬂammatory ileocolonic Crohn’s disease with oropharyngeal
involvement and treatment-refractory pyoderma gangrenosum
(PG). His medical history is signiﬁcant for adrenal insufﬁciency,
vertebral fractures due to osteoporosis, and latent tuberculosis
treated with isoniazid. Surgical history includes a tonsillectomy.
His brother and mother have celiac disease. He is married and
works as a lawyer. He is a lifetime nonsmoker, does not use illicit
drugs, and rarely drinks alcohol. In 2002, at age 14, he was
diagnosed with Crohn’s disease after presenting with abdominal
pain and diarrhea. After his diagnosis, he was treated with prednisone with an excellent response.
He was gradually tapered off of prednisone and transitioned
to budesonide, which he remained on for approximately 1 year

1. Explain the side effects of medications used to treat IBD,
particularly anti-TNFs.
2. Recognize the various types of skin lesions that may occur
in IBD patients, focusing on those that arise among patients
on immunosuppressants.
3. Be cognizant of the presentation and treatment of pyoderma
gangrenosum in IBD patients.
4. Describe the various types of mycobacterial infections that
may occur among IBD patients, especially those that are on
anti-TNFs.
5. Describe the risk factors for developing a Mycobacterial
marinum infection and how it may present
dermatologically.
6. Explain how to diagnose and treat a Mycobacterial marinum infection.
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FIGURE 1. Photograph of right ankle and foot demonstrating erythema, edema and crusted, weeping ulcerations in various stages of
development and healing (July 2013).

FIGURE 2. Follow-up photograph of right foot showing nearly complete
healing after adding antibiotics to his treatment regimen (February 2014).

sulfamethoxazole. In time, his oropharyngeal symptoms resolved
and PG lesions healed (Fig. 2). Unfortunately, the patient developed
multiple vertebral fractures secondary to osteoporosis from chronic
steroid use. We tapered the narcotics that had been started for his
back and PG pain and lowered his prednisone that was started by his
community gastroenterologist, but could not reduce it below 10 mg
because of adrenal insufﬁciency. A repeat colonoscopy at this time
demonstrated healing of the mucosa.
In May 2014, the patient developed nasal swelling and facial
induration treated with oral and topical antibiotics by an otolaryngologist. We discontinued his trimethoprim/sulfamethoxazole secondary to thrombocytopenia and started dapsone, which resulted in
an admission to the University of Maryland Medical Center with
methemoglobinemia. A shave biopsy of the nose performed during
the hospital stay revealed granulomatous dermatitis with features
suggestive of acne rosacea or rosacea fulminans (pyoderma faciale).
A dermatologist started him on topical metronidazole and desonide,
but his lesions worsened. Oral isotretinoin was initiated with
signiﬁcant improvement in his facial and nasal lesions; mild
recurrences were treated effectively with the intralesional steroid
triamcinolone. His antibiotics were alternated because of a potential
drug interaction, but minocycline proved the most effective without
causing side effects.
At that time, we stopped the patient’s cyclosporine at his
request because he was becoming frustrated. Soon thereafter, the
patient developed a “ﬂu-like” illness that precipitated an adrenal
crisis. A neurologist evaluated him for severe headaches and diagnosed him with pseudotumor cerebri. His isotretinoin was discontinued. Two months later, the patient developed a sore throat, lip
swelling, and ulcerations of his lips and oral cavity. A nasal swab
showed positive results for Klebsiella, and the patient was prescribed gentamicin cream and a methylprednisolone (Medrol
Dosepak 2–60 mg/d PO divided q6-24 hr). At this time, the
patient’s inﬂiximab levels were undetectable at trough but without
antibodies. Therefore, he was given an early infusion of 15 mg/kg
of inﬂiximab; his cyclosporine was restarted at a dose of 100 mg in
the morning and 125 mg in the evening; and he was given
www.ibdjournal.org |
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without recurrent symptoms, at which time the medication was
discontinued. The patient was well until about 2007 or 2008,
when he developed recurrent abdominal pain, diarrhea, and
weight loss. After failing azathioprine and steroids, he was started
on adalimumab and responded. In 2010, he developed abdominal
symptoms and PG when backpacking in Europe. He was treated
with prednisone but could not taper below 20 mg per day. A
bacterial superinfection of the PG emerged that was treated with
antibiotics and wound care, and his adalimumab was increased to
weekly dosing.
In 2011, the patient had a positive PPD and was treated with
isoniazid for 9 months. In 2012, he reported worsening abdominal
symptoms. The adalimumab that he had been taking regularly was
increased to 40 mg subcutaneously, weekly. Soon thereafter, he
developed nasal congestion, hoarseness, dysphagia, and odynophagia. An otolaryngology evaluation identiﬁed numerous ulcerations
at the base of the tongue. Biopsies revealed squamous mucosa with
focal necrosis, acute and chronic inﬂammation, and rare epithelioid
histiocytic aggregates, suggestive of oropharyngeal Crohn’s disease. Adalimumab was discontinued and, after failing certolizumab
pegol, the patient was started on inﬂiximab and methotrexate while
his prednisone was increased to 40 mg daily. Nonetheless, the
patient had persistent PG lesions, predominantly on his right lower
extremity, particularly the foot (Fig. 1).
His prednisone was increased to 60 mg daily, methotrexate
and non-steroidal anti-inﬂammatory drugs (NSAIDs) were discontinued, topical tacrolimus was added, and his PG pain was treated
with tramadol. In addition, his inﬂiximab infusions were changed to
every 4 weeks at 10 mg/kg. After initially improving, his PG
worsened. We again stopped the NSAIDs he had started on his own
and tapered his prednisone. We also discontinued his tacrolimus,
changed his inﬂiximab schedule to every 6 weeks at 10 mg/kg, and
started him on minocycline, cyclosporine, and trimethoprim/

Skin Lesions in IBD
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FIGURE 4. Persistent facial edema, erythema, and ulcerations noted
despite treatment with vancomycin and piperacillin/tazobactam (June
2015).

On the medical ﬂoor, his inﬂiximab and cyclosporine were
held while he was treated with vancomycin and piperacillin/
tazobactam. Skin lesion cultures revealed Klebsiella sensitive to
ceftriaxone, and he was treated with ceftriaxone for 10 days. He
was given 3 doses of 0.4 mg/kg of IV immunoglobulin (IV IG)
daily along with oral hydrocortisone 20 mg bid because of adrenal
insufﬁciency. A repeat shave biopsy of the right cheek revealed
fungal folliculitis for which oral ﬂuconazole was initiated. The left
cheek biopsy demonstrated pseudoepitheliomatous hyperplasia
with parakeratosis and heavy mixed inﬂammatory inﬁltrate and
exocytosis of inﬂammatory cells. Special stains for acid-fast
bacilli were positive although Mycobacterium tuberculosis was
not detected on ribosomal RNA. Because of persistent fever,
the patient underwent a pan–computed tomography that was
remarkable only for an enlarged right submandibular lymph node.
At his follow-up clinic appointment, the patient does not
report having fevers or chills, abdominal pain, diarrhea, or
extraintestinal manifestations but described having severe nose,
lip, and oral pain and poor oral intake secondary to both anorexia
and odynophagia/dysphagia.

Dr. Leonard Baidoo
(Northwestern, Gastroenterology)

FIGURE 3. At admission, the patient had facial edema with crusted,
erythematous, fungating nodules with central umbilication along his
bilateral cheeks, nose, and upper lips. Note the deeper ulcerations
adjacent to the nose (May 2015).
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To summarize, this is a patient with Crohn’s disease diagnosed in 2002 who was doing relatively well until around 2007 or
2008. He has oropharyngeal involvement and PG that, based on the
recent photographs, seems to have persisted and gotten considerably
worse. He has become refractory or nonresponsive to virtually all
the anti–tumor necrosis factors (TNFs). In fact, his inﬂiximab has
been started, stopped, and restarted at various doses. He responded
fairly well to cyclosporine, but it was discontinued. So let us go
around to the participating sites and get some feedback on how our
physicians would manage this complicated patient.
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Pneumocystis pneumonia prophylaxis. Despite treatment, the patient’s symptoms worsened. In May 2015, the patient was admitted
to an outside hospital with a 2 to 3 weeks’ history of worsening lip,
nose and cheek lesions, and recent-onset fever. He was treated with
intravenous (IV) vancomycin and piperacillin/tazobactam and
underwent an excisional deep shave biopsy of the left cheek with
cultures for bacterial, fungal, viral, and mycobacterial organisms.
He was discharged on trimethoprim/sulfamethoxazole.
The patient continued to have intermittent fevers at home
and was admitted to the University of Maryland Medical Center
from May 30th until June 8th of 2015 where he was noted to be
febrile and tachycardic in the emergency department. Physical
examination was remarkable for facial edema and crusted,
erythematous, fungating nodules with central umbilication on
his cheeks, nose, and the upper lip (Figs. 3 and 4). Initial laboratory studies were signiﬁcant for a white cell count of 11.8 · 103
cells/mL (normal 3.9–10.7 · 103 cells/mL), hemoglobin of 11.9 g/
dL (normal 13–17 g/dL [men]), hematocrit 27.3% (normal
40%–54% [men]), and C-reactive protein of 7.7 mg/dL (normal
,3.0 mg/dL). An otolaryngologist performed a laryngoscopy that
demonstrated oropharyngeal edema without airway involvement.
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Dr. Hans H. Herfarth (University of North
Carolina, Gastroenterology)

Skin Lesions in IBD

pyoderma, may be he should go on ustekinumab or a different agent
as opposed to an anti-TNF.

It seems to me that the anti-TNFs never really worked, but
the patient improved when the cyclosporine was added to the antiTNF. In the last photographs, the patient looks worse. I am
wondering what the patient’s cyclosporine level was before it was
stopped and also whether you could use tacrolimus to get things
under better control. I also would want to know whether this is an
atypical mycobacterial infection because there were acid-fast
bacilli on staining. I might suggest starting the patient on triple
therapy as treatment.

We have some experience in treating pyoderma with IV IG
although we run into terrible problems in getting insurance coverage
for it. However, we have had success with IV IG although, for one
of our recent patients, it took a while for it to kick in. Other than
that, I think that ustekinumab could be an option although I believe
that his infection is what that needs to be treated ﬁrst.

Dr. Raymond K. Cross (University of
Maryland, Gastroenterology)

Dr. Corey A. Siegel
(Dartmouth, Gastroenterology)

In the past, the patient’s oropharyngeal Crohn’s was responsive to anti-TNF agents, but the pyoderma was not, and he would
get recurrent oropharyngeal symptoms before his inﬂiximab infusions when he was on cyclosporine. This is why he remained on
both medications. We do not think this is M. tuberculosis because
his probe for the ribosomal RNA was negative. Infectious Disease
specialists saw him, and they do not think it is typical mycobacteria
but, rather, an atypical mycobacterial infection. They have been
reticent to start empiric 1-drug or 3-drug therapy until they get it
speciated despite his ongoing symptoms.

I agree with many of the previous comments. I think that
this infection needs to be sorted out. We are talking about trying
all different types of immunosuppressant drugs, but I think that,
ﬁrst, the clinicians from Infectious Disease should give us an idea
of what type of empiric drugs might be used for his infectious
complications. This patient is in bad shape, and I think that we
need to try something. From a bowel standpoint, I like Frank’s
idea of ustekinumab. There are some limited data that we have
discussed in this conference that address the use of ustekinumab
for pyoderma with some success. We have also previously discussed using hyperbaric oxygen for some of our patients who
have severe disease, and it can also be used for pyoderma. There
is almost no downside to using hyperbaric oxygen. I know that
Pittsburgh has access to hyperbaric oxygen, but I am not sure
whether it is available in Maryland. I would try empiric antibiotics, probably triple-drug therapy, going after mycobacteria.
Potentially, I would consider using ustekinumab or hyperbaric
oxygen to get his bowel disease under control. The only other
thing that has not been raised is orofacial granulomatosis, which is
not exactly Crohn’s disease but you treat it like Crohn’s disease
with anti-TNFs in addition to dietary changes, although I do not
think avoiding cinnamon and benzoate products is going to make
much of a difference for this patient. This might be something to
consider when you are waiting for medication to work.

Yes, that was what I thought because we had a similar case
with a patient with pyoderma here who was refractory to therapy
with steroids, cyclosporine, and anti-TNFs. Then on triple
therapy, which is what you would normally do for M. tuberculosis, the PG went away. In the end, it was determined that the
patient had atypical mycobacteria.

Dr. Myron H. Brand (Yale, Gastroenterology)
We agree with what Hans said. This is likely to be some sort
of superinfection in an immunocompromised patient. It is important
to get the opinions of the clinicians of Dermatology and Infectious
Disease because I think we are dealing with an infectious
complication in a patient with Crohn’s disease. I do not think that
this is just his Crohn’s disease. It sounded like his bowel disease was
fairly well-controlled but maybe Ray could tell us some more about
what was going on with his Crohn’s disease. Right now, I do not
think I would be immunosuppressing him until I knew for certain
what was going on from an infectious point of view.

Dr. Alka Goyal (Children’s Mercy Kansas City,
Pediatric Gastroenterology)

Dr. Francis A. Farraye (Boston Medical
Center, Gastroenterology)

Dr. Ioannis E. Koutroubakis (University of
Crete—Greece, Gastroenterology)

We agree with the statements that have been made. These do
not seem to be the typical ear, nose, throat (ENT) and facial
manifestations of oropharyngeal Crohn’s disease. I think that he
needs to have this infection treated, whatever it is. We are thinking
outside the box and considering going for a different drug. Ultimately, if he does have luminal Crohn’s disease or recurrent

Personally, I agree that the ﬁrst thing to do is to treat the
potential infectious etiology. This person had latent tuberculosis
(TB) in the past. We should take into account that, even if his test
results are negative for it, treatment with therapy for tuberculosis
or other atypical mycobacteria is warranted. This would be my
ﬁrst priority. Of course, your choices of inﬂammatory bowel

We were wondering whether leprosy (Mycobacterium leprae)
might be a possibility given this patient’s presentation and facial
appearance. We were also curious about whether genetic testing might
be warranted to evaluate for treatment-resistant Crohn’s disease.

www.ibdjournal.org |
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Dr. Hans H. Herfarth (University of North
Carolina, Gastroenterology)

Dr. Emmanuelle (Manny) Williams (Penn State
Hershey, Gastroenterology)

Rajan et al

disease (IBD) medications are limited in that he has not responded
to anti-TNFs. Although I do not have experience with ustekinumab, I agree that this agent might be a good choice.

Dr. David G. Binion (University of
Pittsburgh, Gastroenterology)

Dr. Leonard Baidoo
(Northwestern, Gastroenterology)
So Ray, the consensus is that you should push your
Infectious Disease colleagues to give this patient some empiric
or speciﬁc treatment. It seems that he has run the course with the
anti-TNFs, and if you need to treat him further for his Crohn’s
disease, an alternative medication might be a good idea. What are
you thinking at this point? Infection? Is this refractory, extraintestinal IBD or something else??

Dr. Raymond K. Cross (University of
Maryland, Gastroenterology)
The rationale for the IV IG was that he clearly needed a break
from immune suppression, and we were convinced that this was

2758

primarily an opportunistic infection that was causing his symptoms.
I have been fairly aggressive with our Infectious Disease colleagues
about getting a medication started, but they have been hesitant to
start any medication for mycobacterial infection.
There is some disagreement between our Dermatology and
Infectious Disease specialists where the biopsies do not seem to be
completely consistent with a mycobacterial infection, even though
the stain is positive. As to David’s point about anemia, he has been
tested for iron-deﬁciency anemia many times, and his ferritin is 300
to 400, so he is not iron-deﬁcient. I am not sure whether he has
been worked up for celiac disease. We also put him on an enteral
diet for 2 to 3 weeks before he re-presented to the hospital as a form
of last-ditch, nonimmunosuppressive treatment.
We gave him some topical budesonide respules because he
was pleading with us for steroids and with his dermatologists for
intralesional steroids, and the respules seemed like a good compromise. Topical therapy also seemed appropriate because I think
some of the oropharyngeal lesions are results of his Crohn’s disease,
whereas the nasal and lip ﬁndings are the opportunistic infection.
After he completes some treatment for the mycobacterial infection,
we will need to transition him to something to treat his Crohn’s
disease. I think ustekinumab is a good idea. We were also thinking
about vedolizumab with the idea that it might be less immunosuppressive. I was trying to think of something less systemically immunosuppressive. The thought was that the IV IG would be temporary
treatment until we address his infection and get him back to some
sort of baseline. At that point, we could institute monotherapy for
his Crohn’s disease or for whatever this is.

Dr. Hans H. Herfarth (University of North
Carolina, Gastroenterology)
Did you recently biopsy the lip and look for granulomas so
that you could be sure that this is Crohn’s disease? That would
better narrow the therapy.

Dr. Raymond K. Cross (University of
Maryland, Gastroenterology)
They swabbed, cultured, and biopsied the left cheek, and it
showed acid-fast bacilli. However, they lost the pathology to the
left cheek. Within the next day or 2, they biopsied the right cheek
and the dermatopathologist thought that the biopsy showed
something more consistent with a fungal infection. This is the
reason that there is disagreement between Dermatology and
Infectious Disease. When I spoke with our gastrointestinal (GI)
pathologist, he said that although they were suspicious for a fungal
infection, there was no way to exclude mycobacteria as a cause.
Personally, I found the biopsies to be more confusing than helpful.

Dr. Douglas J. Hartman (University of
Pittsburgh, Pathology)
It can be difﬁcult to identify rare mycobacterial organisms
in tissue specimens. Even the presence of granulomas does not
always help to separate out these 2 entities. I would recommend
that you do a tissue culture of one of the specimens. Mycobacteria
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Dhyan, you gave us a little bit of information about his
bowel disease but one of the last pieces of objective data that were
presented was that the patient had a hematocrit of 27, which, for
a male patient, implies that there may be some losses coming from
the gastrointestinal tract. If he is in good shape with no obvious
damage to the gut, I would be suspicious about gluten sensitivity. I
know that you mentioned that both his mother and brother have
a history of celiac disease. I do not know whether you have
explored an elimination diet or removing gluten from this patient’s
diet, but I had one patient with similarly severe, treatmentrefractory disease that was put on a gluten-free diet, and she had
complete resolution of skin lesions that had been previously labeled
as pyoderma. The pyoderma involved her abdominal wall at multiple incision sites, and it was highly destructive. Eliminating gluten
is a fairly benign potential solution that could be added to the mix.
Realistically, I do think that this is superinfection. There was
mention that the patient was put on some typical anti-fungal agents.
These medications may not be adequate to cover the potential
superinfections that can accompany this type of a picture. Given the
severity that he is demonstrating, you might consider expanding
fungal coverage to something more potent. I would work with the
infectious disease colleagues and would consider anti-fungal agents
with broader spectrum of activity, such as caspofungin.
Your patient is presenting with an unusual clinical picture with
the need for immunosuppression in the setting of a potential infectious
complication. If you need guidance, you could confer with colleagues
experienced in Solid Organ Transplantation or Infectious Disease
Transplant, because they are likely to have the most knowledge in this
area. When I work with our small bowel transplant team and we see
these types of profound cellulitis infections, the treatment pathway
that is most commonly beneﬁcial is systemic anti-fungal therapy. I am
also fully in favor of IV IG given that it has proven efﬁcacy for
pemphigus but may also help regarding infectious complications.

Inﬂamm Bowel Dis  Volume 22, Number 11, November 2016
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Dr. David Binion (University of
Pittsburgh, Gastroenterology)
The problem with the granulomas detected on histology is
that they might be a physiologic response to infection. Immune
responses to mycobacteria will involve epithelioid granuloma
formation. So I am not sure that doing a biopsy of the lip will
put things into a clean Crohn’s category because there is a hint of
mycobacteria that we are hearing about. There has been literature
over the past 30 years suggesting that atypical mycobacterial infections, such as Mycobacterium paratuberculosis, may contribute
to the etiopathogenesis of Crohn’s disease. Although organisms
like paratuberculosis will not be responsible for most cases of
Crohn’s disease, in all likelihood, there will be rare patients where
mycobacterial superinfection is contributing to the disease.

Dr. Leonard Baidoo
(Northwestern, Gastroenterology)
I am curious to know about the patient’s ethnicity and
recent travel history, given that he had latent TB.

Dr. Ray Cross (University of
Maryland, Gastroenterology)
He is white and was born and raised in the United States.
His only travel history includes the backpacking in Europe that I
mentioned as being when the foot lesions developed. More
recently, he was in Paris for his honeymoon. He did not report
any other type of travel.

FOLLOW-UP
Mycobacterium marinum was eventually isolated from the
patient’s lesions. A 6-month medical regimen for the treatment of
M. marinum was initiated, which included a combination of
ethambutol, minocycline, and azithromycin. The therapy resulted
in near resolution of the facial lesions (Fig. 5). However, the
patient manifested worsening luminal symptoms and migratory
arthritis and was therefore restarted on inﬂiximab 10 mg/kg, every
6 weeks. As of November 2015, he was doing well and has had
no recurrence of either PG or M. marinum infection.

DISCUSSION
PG is a less common but serious, extraintestinal manifestation of IBD.1,2 PG is a neutrophilic dermatosis with lesions that

FIGURE 5. Note the near complete resolution of the patient’s facial
edema and ulcerations after 6 months of medical therapy directed
toward Mycobacterium marinum, including ethambutol, minocycline,
and azithromycin (January 2016).

manifest as deep, painful ulcerations that may be a treatment
challenge. Symptoms that often accompany PG include malaise,
fever, myalgias, and arthralgias, which are also symptoms of
IBD.1 Similarly, infection of PG lesions may not cause profound
changes in a patient’s symptoms. The mainstay of treatment for
PG is immunosuppressants with anti-TNFs showing signiﬁcant
effectiveness in resolving the lesions.3–6 However, superinfection
of PG lesions often requires stopping immunosuppressants until
the underlying infection has been adequately treated. The patient
described in this case had been immunosuppressed for many
years, receiving inﬂiximab, adalimumab, and cyclosporine, alone
or in combination, during the course of his illness.
Although TNF-alpha inhibitors (anti-TNF) therapies have
caused a paradigm shift in the management of IBD and other
chronic inﬂammatory disease states, clinicians must be aware of
their potentially serious side effects. Infections, drug-induced lupus,
serum sickness-like reactions, demyelinating diseases, and skin
cancer are examples of more serious adverse reactions that have
been observed with anti-TNF therapy.7–13 Dermatologic manifestations from anti-TNF therapy have been well-documented and can
range from simple injection-site reactions to psoriasis, erythema
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do not culture very well, which is another diagnostic problem.
Once you start down this atypical mycobacterial wormhole, you
can get stuck because the diagnoses can be very difﬁcult to separate. Although you know this is not TB, this does not help you
with the other types of mycobacterial organisms. If they can get
some culture, they can type it because they are doing more molecular evaluations of mycobacteria. However, I would process the
sample through Microbiology and not through Anatomical
Pathology or Dermatopathology, because the microbiologists are
going to be more likely to give you a treatable organism.
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of cyclosporine and an anti-TNF could have increased the risk and
severity of his infection. Health care providers need to be vigilant
in monitoring for opportunistic infections in patients with IBD
taking immunosuppressants.
Patients with M. marinum infection involving the face
might be misdiagnosed with pyoderma faciale if appropriate cultures and stains for acid-fast bacilli are not performed. Notably,
routine PPD skin testing does not predict infection with or reactivation of the various types of nontuberculous mycobacteria,
including M. marinum. Misdiagnosis can lead to continuation of
potentially detrimental immunosuppressive therapy and failure to
initiate appropriate antimycobacterial treatment. Discontinuing
immune suppression is recommended when the diagnosis of
M. marinum is suspected. The decision to resume immunosuppressants depends on the presence and severity of IBD symptoms,
the severity of disease course, and whether there is clinical
improvement of the M. marinum lesions on antimycobacterial
therapy.32,33 In our case, the rapid recurrence of symptoms and
severity of the patient’s Crohn’s disease prompted restarting antiTNF monotherapy a few weeks after completing treatment for
M. marinum.

EDITOR’S COMMENT
Dermatologic manifestations are common in patients with
IBD, and some centers now have dermatologists who specialize in
IBD-related skin problems. When patients with IBD present with
skin ulcerations, there is a wide differential diagnosis from
familiar PG lesions to rare metastatic cutaneous Crohn’s disease.2,34 Crohn’s disease involving the upper GI tract comprises
inﬂammation anywhere from the mouth to the jejunum, typically
with concomitant lower GI tract disease.35 There is signiﬁcant
overlap between orofacial Crohn’s disease and PG as well as other
confounding entities, such as Bechet’s disease, orofacial granulomatosis, lichen planus, herpes simplex virus, and even squamous
cell cancer related to human papillomavirus.36,37 Discerning the
etiology of skin lesions in patients with IBD can be difﬁcult,
particularly among those with a history of PG. In a study of 95
individuals with skin ulcerations resembling PG, ﬁnal diagnoses
included cancer, vascular occlusive or venous disease, vasculitis,
primary infection, drug-induced or exogenous tissue injury, and
other inﬂammatory disorders.38 Therefore, not all painful skin
lesions are pyoderma.
Patients with IBD taking immunosuppressant anti-TNFs
have a heightened risk of bacterial, fungal, mycobacterial, and
viral illnesses.39 Because of the increasing numbers of rare
mycobacterial infections that are being observed among immunosuppressed patients with IBD, providers should be aware of
this, particularly in patients with skin lesions that are not responsive to IBD therapies or that worsen with these treatments. A
multidisciplinary approach to managing orofacial/cutaneous
IBD and infections may include seeking consultation from
Dermatology, Infectious Disease, Microbiology, and Oromaxillofacial specialists.
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multiforme, and eczema.14–17 Dermatologic responses such as
Hodgkin-type lymphoproliferative skin disorders and opportunistic
infections involving the skin may occur secondary to the immunosuppressive effect of anti-TNF therapy.15
Mycobacterial infections are frequently reported opportunistic infections in patients receiving anti-TNFs, and anti-TNF
therapy may precipitate their reactivation.13,18–20 Although M.
tuberculosis is the most common mycobacterial infection associated
with anti-TNF therapy, it rarely causes dermatologic manifestations,
even when disease is disseminated. More often, nontuberculous
mycobacteria infections are implicated when extrapulmonary infections arise. When nontuberculous mycobacteria cause a cutaneous
infection, M. marinum is the most likely causative agent although
Mycobacterium chelonae, Mycobacterium mucogenicum, and
Mycobacterium abscessus have also caused skin infections in patients taking anti-TNF medications.21–23
Because TNF serves an important role in maintaining
granuloma formation and preventing mycobacterial growth, lymphocutaneous spread of nontuberculous mycobacteria has been
increasingly noted among patients receiving anti-TNF therapy over
the last 2 decades.19,24,25 In 2009, Winthrop et al19 published results
of their review of the US Food and Drug Administration MedWatch
database reports of nontuberculous mycobacteria infections in patients receiving anti-TNF therapy. During the 9-year period from
1997 to 2006, there were 239 cases of nontuberculous mycobacteria
reported in patients receiving anti-TNF therapy. Of these cases,
nearly 75 percent were associated with inﬂiximab, and the predominant causative organism was Mycobacterium avium. The third most
common nontuberculous mycobacteria infection was M. marinum,
which was also the most likely one to cause skin lesions.
M. marinum is an aquatic mycobacterium whose natural
habitat is fresh or salt water, especially reservoirs of water that
are not frequently replenished.16,26 Infection with M. marinum in
humans typically occurs when the organism is present in contaminated water and inoculates an area of skin break down or puncture; initially, it manifests as sporotrichotic lymphangitis.24,25,27
Some cases of M. marinum infection occur when there is a known
exposure to ﬁsh ﬁns or water containing ﬁsh. For example, in
2010, Ramos et al28 published a case report of M. marinum infection causing painful suppurative papules and nodules on the forearm of a Crohn’s disease patient on inﬂiximab that was caring for
ﬁsh in a domestic aquarium. Although the patient described in this
case did not report recreational or occupational exposure to a body
of water, infection has been shown to occur at higher rates in
those on anti-TNF agents.16,24,29,30
Although the prevalence of M. marinum is rare, cases of
M. marinum are increasingly being noted both in immunocompetent and immunosuppressed hosts, such as transplant patients.27,31
Clinicians should be cognizant of this mycobacterium, particularly in immunosuppressed patients with a history of ulcerative
skin lesions, exposure to brackish water, or a history of pyoderma
faciale.6,7 There are no data to support a heightened risk of infection with M. marinum in patients on dual immunosuppression, as
our patient was. Nonetheless, it is plausible that the combination
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IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Crohn’s Disease Patient:
You Hear Hoof Beats and Discover a Zebra
INSTRUCTIONS FOR OBTAINING AMA PRA CATEGORY 1 CREDITS™
Inﬂammatory Bowel Diseases includes CME-certiﬁed content that is designed to meet the educational needs of its readers. This
article is certiﬁed for 2 AMA PRA Category 1 Credits™. This activity is available for credit through 10/19/2017.™

Credit Designation Statement
Lippincott Continuing Medical Education Institute, Inc designates this journal-based CME activity for a maximum of 2 AMA PRA
Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To earn CME credit, you must read the article in Inﬂammatory Bowel Diseases and complete the quiz, answering at least 75 percent of
the questions correctly. For more information on this IBD CME educational offering, visit the Lippincott CMEConnection portal
at http://cme.lww.com/browse/sources/150 to register online and to complete the free CME activity online.
IBD is also pleased to inform our readers that this CME activity is now eligible for the American Board of Internal Medicine’s (ABIM)
Maintenance of Certiﬁcation (MOC) credit based on the most recent collaboration between the ABIM and the ACCME. In order to receive
ABIM MOC for this CME activity each participant will need to make sure that the information on their proﬁle for the CME platform (where this
activity is located) is updated with 1) Their DOB - Month and Day only and 2) That they have selected that they are board certiﬁed in the proﬁle
via the ABIM. When this selection is made they will be required to enter their ABIM number. (Which is assigned via the ABIM). Participants
will earn MOC points equivalent to the amount of CME credits claimed for the activity. The Lippincott Continuing Medical Education Institute
will submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

LEARNING OBJECTIVES
After completing this IBD LIVE-CME activity, physicians should be better able to:

1. Explain the side effects of medications used to treat IBD, particularly anti-TNFs.
2. Recognize the various types of skin lesions that may occur in patients with IBD, focusing on those that arise among patients on
immunosuppressants.
3. Be cognizant of the presentation and treatment of PG in patients with IBD.
4. Describe the various types of mycobacterial infections that may occur among patients with IBD, especially those that are on anti-TNFs.
5. Describe the risk factors for developing a Mycobacterial marinum infection and how it may present dermatologically.
6. Explain how to diagnose and treat a M. marinum infection.
1. You have a patient with severe Crohn’s disease that you would like to start on the anti-TNF medication adalimumab. Which of
the following is not a recognized potential side effect of anti-TNF medications that you will discuss with your patient?
(a) Injection-site reactions
(b) Osteoporosis
(c) Increased risk of infections
(d) Eczema
Please see the following references for further study:
1. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to inﬂiximab: a large center
experience. Am J Gastroenterol. 2003;98:1315–1324.
2. Ali T, Kaitha S, Mahmood S, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug, Healthcare and
Patient Safety. 2013;5:79–99.
3. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inﬂammatory bowel
disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
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2. Which of the following patient factors is a contraindication for initiating anti-TNF therapy?
(a) Taking a thiopurine concomitantly
(b) Previously developing antibodies to a different anti-TNF agent
(c) Having a positive PPD
(d) Having a history of corticosteroid use

3. Which mycobacterium species is not commonly associated with skin lesions?
(a) Mycobacterium leprae
(b) Mycobacterium marinum
(c) Mycobacterium mucogenicum
(d) Mycobacterium tuberculosis
Please see the following references for further study:
1. Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–682.
2. Shehan JM, Sarma DP. Mycobacterium mucogenicum: report of a skin infection associated with etanercept. Dermatol
Online J. 2008;14:5.
3. Polycarpou A, Walker SL, Lockwood DN. New ﬁndings in the pathogenesis of leprosy and implications for the
management of leprosy. Curr Opin Infect Dis. 2013;26:413–419.
4. Your ulcerative colitis patient develops PG of the right extremity and responds well to medication. Which of the following
agents has shown good efﬁcacy in treating PG and is the medication this patient might be using?
(a) Caspofungin
(b) Isoniazid
(c) Inﬂiximab
(d) Vancomycin
Please see the following references for further study:
1. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Inﬂiximab for treatment of pyoderma gangrenosum
associated with inﬂammatory bowel disease. Am J Gastroenterol 2003;98: 1821–6.
2. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181–4.
5. Which of the following entities could be misdiagnosed as pyoderma gangrenosum?
(a) Opportunistic infections involving the skin
(b) Orofacial granulomatosis
(c) Behcet’s disease
(d) All the above
Please see the following references for further study:
1. Weenig RH, Davis MD, Dahl PR, et al. Skin ulcers misdiagnosed as pyoderma gangrenosum. New Eng J Med.
2002;347:1412–1418.
2. Tavarela Veloso F. Review article: skin complications associated with inﬂammatory bowel disease. Aliment Pharmacol
Ther. 2004;20(Suppl 4):50–53.
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2. Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest.
2009;119:1079–1082.
3. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inﬂammatory
bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
4. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inﬂammatory
bowel disease treated with inﬂiximab. Gut. 2014;63:1258–1264.
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3. Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and antiTNF therapy in inﬂammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002–1024.
4. Akay N, Boyvat A, Heper AO, et al. Behcet’s disease-like presentation of bullous pyoderma gangrenosum associated
with Crohn’s disease. Clin Exp Dermatol. 2006;31:384–386.

Please see the following references for further study:
1. Ferreira J, Grochowsky J, Krakower D, et al. Mycobacterium marinum: an increasingly common opportunistic infection
in patients on inﬂiximab. Am J Gastroenterol. 2012;107:1268–1269.
2. Danko JR, Gilliland WR, Miller RS, et al. Disseminated Mycobacterium marinum infection in a patient with rheumatoid
arthritis receiving inﬂiximab therapy. Scand J Infect Dis. 2009;41:252–255.
3. Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and
review of the literature. Transpl Infect Dis. 2008;10:358–363.
4. Fallon JC, Patchett S, Gulmann C, et al. Mycobacterium marinum infection complicating Crohn’s disease, treated with
inﬂiximab. Clin Exp Dermatol. 2008;33:43–45.
5. Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inﬂammatory bowel disease therapy. Inﬂamm
Bowel Dis. 2014;20:196–212.
7. Which of the following is the most reliable method for diagnosing a Mycobacterium marinum infection?
(a) Characteristic crusted, erythematous skin ulcerations
(b) A positive PPD
(c) Acid-fast bacillus smear and culture and sensitivity for Mycobacterium marinum
(d) Histology from colonoscopic biopsy showing distorted architecture, numerous crypt abscesses, and granuloma formation.
Please see the following references for further study:
1. Fallon JC, Patchett S, Gulmann C, et al. Mycobacterium marinum infection complicating Crohn’s disease, treated with
inﬂiximab. Clin Exp Dermatol. 2008;33:43–45.
2. Lahey T. Invasive Mycobacterium marinum infections. Emerg Infect Dis. [serial online]. 2003. Available at: http://
wwwnc.cdc.gov/eid/article/9/11/03-0192. Accessed June 15, 2016.
3. Ramos JM, Garcia-Sepulcre MF, Rodriguez JC, et al. Mycobacterium marinum infection complicated by anti-tumor
necrosis factor therapy. J Med Microbiol. 2010;59:617–621.
8. Your Crohn’s disease patient was recently diagnosed with a Mycobacterium marinum infection. Which medication would not
be used to treat the M. Marinum infection?
(a) Ethambutol
(b) Certolizumab pegol
(c) Minocycline
(d) Azithromycin
Please see the following references for further study:
1. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother. 2007;8:2965–2978.
2. Braback M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatiﬂoxacin, gemiﬂoxacin, levoﬂoxacin, linezolid, moxiﬂoxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to
reference macrolides and quinolones. Antimicrob Agents Chemother. 2002;46:1114–1116.
3. Lahey T. Invasive Mycobacterium marinum infections. Emerg Infect Dis. [serial online]. 2003. Available at:
http://wwwnc.cdc.gov/eid/article/9/11/03-0192. Accessed June 15, 2016.
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6. Which of the following individuals would be most susceptible to developing an opportunistic Mycobacterium marinum
infection?
(a) A 36-year-old man with Crohn’s disease on inﬂiximab for 3 years who is an avid ﬂy-ﬁsherman.
(b) A 22-year-old woman with ulcerative proctosigmoiditis that is well controlled with budesonide foam.
(c) A healthy 26-year-old woman scuba diving instructor.
(d) A 19-year-old man newly diagnosed with Crohn’s disease with no medical history that is planning to start treatment with
the immunomodulator azathioprine.

